grant
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention
Organization UNIVERSITY OF NEBRASKA MEDICAL CENTERLocation OMAHA, UNITED STATESPosted 15 May 2024Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY20260-11 years old12-20 years oldAdolescenceAdverse ExperienceAdverse effectsAdverse eventAgeAnti-Retroviral AgentsApoptosisApoptosis PathwayAssayAttenuatedBasic ResearchBasic ScienceBechuanalandBehavioralBindingBioassayBiological AssayBloodBlood PlasmaBlood Reticuloendothelial SystemBody TissuesBotswanaBrainBrain Nervous SystemBrain imagingBrain regionCatalytic CoreCatalytic DomainCatalytic RegionCatalytic SiteCatalytic SubunitCell Growth in NumberCell MultiplicationCell ProliferationCells Placenta-TissueCellular ProliferationChildChild YouthChildhoodChildren (0-21)ClinicalClinical DataClinical ResearchClinical StudyCombined Modality TherapyConceptionsCountryDWI (diffusion weighted imaging)DWI-MRIDataDevelopmentDiffusion MRIDiffusion Magnetic Resonance ImagingDiffusion Weighted MRIDiffusion weighted imagingDiffusion-weighted Magnetic Resonance ImagingDoseDrug DeliveryDrug Delivery SystemsDrug ExposureDrug KineticsDrug usageDrugsElectrophysiologyElectrophysiology (science)EmbryoEmbryonicEmbryonic TissueEncapsulatedEncephalonEvaluationExposure toFemaleFemale of child bearing ageFemale of childbearing ageFundingGeneticGestationGrantH+ elementHIV individualsHIV infected individualsHIV infected personsHIV interventionHIV peopleHIV positive individualsHIV positive peopleHIV therapeuticHIV therapyHIV treatmentHIV-1HIV-1 interventionHIV-1 therapeuticHIV-1 therapyHIV-1 treatmentHIV-IHIV1Human Immunodeficiency Virus Type 1Human Immunodeficiency Virus therapyHuman Immunodeficiency Virus treatmentHuman Immunodeficiency Virus-1Human immunodeficiency virus 1Hydrogen IonsImmunoblottingImpairmentInfectionInhibition of Matrix MetalloproteinasesInhibition of Matrix Metalloproteinases PathwayInjectableIntegrase InhibitorsKnowledgeLearningLinkMMP InhibitorMMPsMR ImagingMR SpectroscopyMR TomographyMRIMRIsMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMatrix Metalloproteinase InhibitorMatrix MetalloproteinasesMeasurementMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMedulla SpinalisMemoryMemory DeficitMemory impairmentMetabolicMiceMice MammalsMolecularMolecular InteractionMonitorMothersMultimodal TherapyMultimodal TreatmentMurineMusNMR ImagingNMR TomographyNNRTI-resistanceNNRTI-resistantNational Institutes of HealthNerve CellsNerve UnitNeural CellNeural DevelopmentNeurocyteNeurodevelopmental DeficitNeurodevelopmental ImpairmentNeurologicNeurologicalNeuronsNeurophysiology / ElectrophysiologyNormal PlacentomaNorth AmericaNuclear Magnetic Resonance ImagingOral AdministrationOral Drug AdministrationOutcomePLWHPWHPathologyPathway interactionsPeripheralPersonsPharmaceutical PreparationsPharmacokineticsPhysiologicPhysiologicalPlacentaPlacenta Embryonic TissuePlacentomePlasmaPlasma SerumPoloxamersPolymerase Chain ReactionPopulationPregnancyPregnant WomenPrevention therapyProgrammed Cell DeathPropertyProtonsRadialRadiusRecommendationRecurrenceRecurrentRegimenReportingResearchResearch ResourcesResistanceResourcesReticuloendothelial System, Serum, PlasmaRiskRodent ModelSafetySchemeScienceSpinal CordStructural defectStructural malformationStructureSystemTestingTherapeuticTherapeutic InterventionTissuesToxic effectToxicitiesUnited States National Institutes of HealthValidationVibrissaeWeight GainWeight IncreaseWestern BlottingWestern ImmunoblottingWhiskersZeugmatographyadolescence (12-20)agesanti-retroviralarmattenuateattenuatesbehavior outcomebehavioral outcomebody weight gainbody weight increasebrain healthbrain tissuebrain visualizationchildbearing ageclinical relevanceclinically relevantcombination therapycombined modality treatmentcombined treatmentcritical perioddMRIdesigndesigningdevelopmentaldevelopmental neurotoxicitydiffusion tensor imagingdrug usedrug/agentelectrophysiologicalembryo tissueexpectant motherexpectant womenexpecting motherexpecting womenfertile agefetalhigh definitionhigh-resolutionimprovedin uteroindividuals infected with HIVindividuals who are pregnantindividuals with HIVindividuals with human immunodeficiency virusinfancyinfantileinterestintervention therapyintraoral drug deliverykidsmalformationmemory dysfunctionmouse developmentmulti-modal therapymulti-modal treatmentnano formulationnanoformulationneural inflammationneurobehavioralneurobehavioral testneurodevelopmentneuroinflammationneuroinflammatoryneuron developmentneuron toxicityneuronalneuronal developmentneuronal toxicityneuropathologicneuropathologicalneuropathologyneuroprotectionneuroprotectiveneuropsychiatricneuropsychiatryneurotoxicitynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-nucleoside reverse transcriptase inhibitor resistancenon-nucleoside reverse transcriptase inhibitor resistantnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwaypediatricpeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople who are pregnantpeople with HIVpeople with human immunodeficiency viruspost-natal developmentpostnatalpostnatal developmentpre-clinical studypreclinical studypregnantpregnant femalespregnant motherspregnant peoplepregnant populationsprenatalpreventpreventingprotein blottingpupreproductive agereproductive yearsresistance to non-nucleoside reverse transcriptase inhibitorresistance to therapyresistantresistant to non-nucleoside reverse transcriptase inhibitorresistant to therapyresponsestructural abnormalitiesstructural anomaliessurfactanttheoriestherapeutic resistancetherapy resistantthose who are pregnanttranscriptomicstranslation strategytranslational approachtranslational impacttranslational strategytreat HIVtreat Human Immunodeficiency Virustreatment guidelinestreatment resistanceunbornvalidationswomen of child bearing agewomen of childbearing agewomen who are pregnantwt gainyounger ageyoungster♀
Description preview
Project Summary
Background: Dolutegravir (DTG) is a first-line antiretroviral drug used in combination therapy for the treatment
of human immunodeficiency virus type-1 (HIV-1) infection. Due to the roll out of generic DTG-based regimen, its
inclusion in national treatment guidelines and rising pretreatment resistance to non-nucleoside reverse…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click